Clinical Trial: Williams Syndrome (WS) and Supravalvular Aortic Stenosis (SVAS) DNA and Tissue Bank
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational
Official Title: Williams Syndrome (WS) and Supravalvular Aortic Stenosis (SVAS) DNA and Tissue Bank
Brief Summary:
Background:
DNA tells the body how to grow and function. Williams-Beuren syndrome (WS) and Supravalvular Aortic Stenosis (SVAS) are rare diseases caused by changes in a part of a person s DNA. Symptoms of both conditions include vascular problems including narrow blood vessels and supravalvular aortic stenosis (SVAS) or supravalvular pulmonary stenosis. Individuals with WS may also have developmental challenges and personality differences. Researchers at the NIH want to find out why only some people with WS and SVAS have severe symptoms. They want to collect samples and data to see what DNA or environmental changes affect the severity of the disease.
Objective:
To identify the DNA differences or environmental changes that change the severity of WS and SVAS from person to person.
Eligibility:
People ages 0 85 with either WS, SVAS, and/or an SVAS-like condition
Children and people with WS must have a parent or legal guardian to consent or help answer questions.
Design:
Participants will be screened with questions and medical history.
Participants will have a 60-minute visit. They will provide blood or saliva samples.
They or their parent/guardian will:
Answer questions about how WS and SVAS affect them.
Sign a form releasing their medical records for the study.
If participant s regular
Detailed Summary:
Our goal with the Williams syndrome (WS) and Supravalvular Aortic Stenosis (SVAS), deoxyribonucleic acid (DNA) and Tissue Bank is to collect enough samples from individuals with this rare condition to ask questions about the genes that cause the many WS and SVAS related phenotypes, and to determine the genetic and environmental changes that modify the severity of disease from person to person. In addition, we would like to learn more about the natural history of these conditions and if there are environmental or genetic signatures that are associated with symptom presence.
The protocol detailed here will provide for the collection of historical information, laboratory and imaging data, DNA and tissue to perform these studies now and in the future. Because technology changes rapidly and because this is a rare condition, our goal is to generate a collection that will be available for analysis for many years.
In addition to DNA and tissue collection proposed, we would like to begin to use the specimens collected here to continue to ask questions about modifiers of vascular disease severity as well as effects on other organ systems in WS and SVAS.
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Current Primary Outcome: The overall objective of this study is to collect historical information and to bank DNA, cells and tissue from individuals with Williamssyndrome and SVAS to facilitate future research into the many phenotypes seen in these individuals. [ Time Frame: ongoing ]
Original Primary Outcome: Same as current
Current Secondary Outcome: To identify genetic and environmental factors that contribute to the variability in different phenotypes in individuals with WS, SVAS, andSVAS-like conditions [ Time Frame: ongoing ]
Original Secondary Outcome: Same as current
Information By: National Institutes of Health Clinical Center (CC)
Dates:
Date Received: March 8, 2016
Date Started: February 23, 2016
Date Completion: September 25, 2025
Last Updated: April 21, 2017
Last Verified: April 17, 2017
